Technical Center

In the Saudi Food and Drug Authority (SFDA) regulatory framework, bacterial endotoxin control has become an essential requirement for many medical devices intended for clinical use in Saudi Arabia. Products that directly contact blood circulation, damaged tissue, or sterile body cavities must demonstrate strict compliance with international biocompatibility and sterility standards.

The primary objective of Bacterial Endotoxin Testing (BET) is to control the risk of pyrogens in pharmaceutical products and to prevent serious adverse reactions in humans, such as fever and shock. According to major pharmacopoeial standards, including the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), medicinal products that directly enter the bloodstream, come into contact with mucous membranes or damaged tissues, or are used in surgical or implantable procedures are subject to mandatory endotoxin testing.

The safety of parenteral medicines and medical devices is heavily dependent on the rigorous detection of bacterial endotoxins, which can cause severe pyrogenic reactions if present in released products. 

BETMAT Biotechnology is committed to advancing bacterial endotoxin testing (BET) through innovative, animal-free technologies that meet the highest global standards of safety and scientific integrity. The publication of the United States Pharmacopeia (USP) Chapter <86>, “Bacterial Endotoxins Test Using Recombinant Reagents”, marks a significant step forward in the modernization of endotoxin testing methodologies.

The primary objective of Bacterial Endotoxin Testing (BET) is to control the risk of pyrogens in pharmaceutical products and to prevent serious adverse reactions in humans, such as fever and shock. According to major pharmacopoeial standards, including the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), medicinal products that directly enter the bloodstream, come into contact with mucous membranes or damaged tissues, or are used in surgical or implantable procedures are subject to mandatory endotoxin testing.

In the performance of bacterial endotoxin test (BET) assays, essential depyrogenated supplies include endotoxin-free water, endotoxin-free glass test tubes, pyrogen-free pipette tips, pyrogen-free microplates, and endotoxin-free sample bottles. All aforementioned items are critical for ensuring assay accuracy, as depyrogenation is a mandatory requirement for BET-related materials.

The kinetic chromogenic LAL assay is a fully compendial, quantitative bacterial endotoxin testing (BET) method widely adopted globally across medical devices, parenteral pharmaceuticals, biologics, and advanced therapies. It is recognized by USP <85>, EP 2.6.14, CP1143, JP 4.01, and WHO guidelines as an equivalent alternative to gel-clot and turbidimetric methods, with increasing preference for its quantitative precision, high sensitivity ( 0.005 EU/mL, even 0.001EU/ml ), and automation capabilities.

Key Characteristics & Classification of LAL Reagents

Pyrogen and endotoxin detection is a fundamental requirement in pharmaceutical manufacturing, biologics production, medical device processing, and intravenous solution quality control. Pyrogens—substances that induce fever - include both endotoxin, a heat-stable lipopolysaccharide (LPS) component of Gram-negative bacterial cell walls, and non-endotoxin pyrogens (NEP) such as lipoteichoic acid, peptidoglycan fragments, microbial debris, and certain chemical contaminants. Because pyrogen contamination poses severe clinical risks such as fever, shock, and inflammatory cascade activation, sensitive and physiologically relevant detection assays are mandated by global pharmacopeias.

Running a BET (Bacterial Endotoxin Test) (also called LAL test) requires a number of specialized reagents, consumables, and equipment to ensure accuracy, sensitivity, and to avoid contamination.